Vaxart appoints Phillip Lee as CFO; interim CFO Fuad Ahmad steps down

Vaxart, Inc.

Phillip Lee appointed CFO, Principal Accounting Officer, and Principal Financial Officer effective Dec 15, 2022.
Lee previously CFO at Clover Biopharmaceuticals; brings ~15 years biotech finance experience.
Lee receives $420K base salary, 40% target bonus, option for 412,500 shares, and 68,750 RSUs.
Fuad Ahmad ceased as Interim CFO on same date.
Press release issued Dec 19, 2022.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Phillip E. Lee

Chief Financial Officer, Principal Accounting Officer, and Principal Financial Officer

VXRT · Vaxart, Inc.

Effective: 2022-12-15
Filed: December 19, 2022, 6:59 PM ET

On December 15, 2022 (the “ Start Date ”), Vaxart, Inc. (the “ Company ”) appointed Phillip E. Lee as the Company’s Chief Financial Officer and as the Company’s Principal Accounting Officer and Principal Financial Officer.

Departed (interim)

Fuad Ahmad

Interim Chief Financial Officer, Principal Accounting Officer, and Principal Financial Officer

VXRT · Vaxart, Inc.

Effective: 2022-12-15
Successor: Phillip E. Lee
Filed: December 19, 2022, 6:59 PM ET

As of December 15, 2022, Fuad Ahmad ceased to serve as the Company’s Interim Chief Financial Officer, Principal Accounting Officer, and Principal Financial Officer.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Phillip E. Lee was appointed as Chief Financial Officer, Principal Accounting Officer, and Principal Financial Officer at Vaxart, Inc..

Action: appointed
Role: Chief Financial Officer, Principal Accounting Officer, and Principal Financial Officer

Exact text from the filing

On December 15, 2022 (the “ Start Date ”), Vaxart, Inc. (the “ Company ”) appointed Phillip E. Lee as the Company’s Chief Financial Officer and as the Company’s Principal Accounting Officer and Principal Financial Officer.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Fuad Ahmad departed as Interim Chief Financial Officer, Principal Accounting Officer, and Principal Financial Officer at Vaxart, Inc..

Action: ceased
Role: Interim Chief Financial Officer, Principal Accounting Officer, and Principal Financial Officer

Exact text from the filing

As of December 15, 2022, Fuad Ahmad ceased to serve as the Company’s Interim Chief Financial Officer, Principal Accounting Officer, and Principal Financial Officer.

View on SEC.gov

Vaxart, Inc. filing history →

Source: SEC EDGAR

accession 0001437749-22-029381

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.